Developing new methods for producing heparin without using animal tissues
Official title: Approaches to enable large scale heparin bio-manufacturing
Funded at Bioparin, LLC · NIH-11067878 · Data updated 2026-11-12
This study is working on a new way to make heparin, an important medicine for people with blood clotting issues, using advanced technology that doesn't depend on animal parts, so that patients can have a steady and safe supply of this vital treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioparin, LLC NIH-funded |
| Lab location | 1 site (Cottonwood Heights, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $306,656 |
| NIH project number | 1R41HL177991-01 |
| Project ID | NIH-11067878 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients requiring anticoagulant therapy for conditions such as thrombosis or other blood coagulation disorders.
✕Less likely to help
Patients who do not require anticoagulant medications or have contraindications to heparin will not benefit from this research.
What this research studies
This research focuses on creating large-scale production methods for heparin, a critical anticoagulant used to treat blood clotting disorders. It aims to develop biomanufacturing techniques that do not rely on animal tissues, addressing concerns about supply chain vulnerabilities and ethical sourcing. By utilizing advanced biotechnology and bioreactors, the project seeks to ensure a stable and safe supply of heparin for medical use. Patients may benefit from more reliable access to this essential medication.
Why it matters
Potential benefit: If successful, this research could provide a sustainable and ethical source of heparin, improving patient access to vital anticoagulant treatments.
How similar studies have gone: While there have been efforts to develop alternative heparin sources, this approach is innovative and aims to address significant supply chain issues, making it a novel endeavor.
Where this research is happening
-
Bioparin, LLC
Cottonwood Heights, United States Active
Researchers
- Principal investigator: Capila, Ishan — Bioparin, LLC
- Study coordinator: Capila, Ishan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.